A new review article published in Genes & Diseases highlights a rapidly emerging frontier in oncology: the dynamic and influential relationship between nerves and tumours.

This evolving field is reshaping how scientists and clinicians understand cancer progression, revealing that tumours are not isolated masses but part of a complex, interactive tumour microenvironment that includes neural networks alongside immune and stromal components.

The article underscores how nerve–tumour interactions play a critical role in shaping disease behaviour.

Signals originating from the peripheral nervous system can directly influence cancer cell proliferation, drive metastasis, and contribute to treatment resistance.

At the same time, tumours actively remodel nearby nerves, creating a bidirectional communication loop that accelerates disease progression.

Three major processes define this interaction: perineural invasion, axonogenesis, and neurogenesis.

These mechanisms collectively enable tumours to invade nerve structures, stimulate the growth of new nerve fibres, and even generate entirely new neural connections.

Such processes are strongly associated with more aggressive disease and poorer outcomes across multiple cancer types.

Beyond direct tumour effects, the review emphasises the broader impact of neural signalling within the tumour microenvironment.

Neurotransmitters and neuropeptides released by nerves influence immune cells, stromal cells, and blood vessels, reshaping the local environment to favour tumour survival and immune evasion.

This intricate neuro-immune crosstalk represents a crucial but underexplored dimension of cancer biology.

Importantly, these discoveries are opening new opportunities for therapeutic innovation.

Strategies that disrupt nerve signalling, modulate neurotransmitter pathways, or target nerve growth factors are emerging as promising approaches.

Some existing neuroactive drugs are already being explored for their ability to interfere with tumour-supporting neural activity, while nerve-targeted interventions may also help alleviate cancer-associated pain.

Advances in technologies such as single-cell sequencing, spatial transcriptomics, and neural tracing are accelerating progress in this field, allowing researchers to map and manipulate nerve–tumour interactions with unprecedented precision.

These tools are expected to drive the next wave of discoveries and clinical applications.

Overall, the review positions the nerve–tumour axis as a transformative concept in modern oncology, with the potential to redefine treatment strategies and improve patient outcomes by targeting an often-overlooked component of cancer biology.

Source: Genes & Diseases